Skip to content
Biotech Industry Examiner
News
Funding
Aging Science
Genomics
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
News
Funding
Aging Science
Genomics
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
Menu
News
Funding
Aging Science
Genomics
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
Menu
M&A & Partnerships
Biotech Stocks
AI in Biotech
CRISPR
Food Biotech
Insights
Longevity
Neuroscience
Precision Medicine
Psychology
Startup
Aging Science
AI in Biotech
Biotech Stocks
CRISPR
Food Biotech
Funding
Genomics
Insights
Longevity
M&A & Partnerships
Neuroscience
News
Precision Medicine
Psychology
Startup
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
subscribe now
Search
Search
Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier
Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?
From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins
MOST POPULAR
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
From Platform to Precision: The $800M Bet Transforming Biotech Investing
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)
Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
News
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Dermatology’s next play: bispecifics that shut down OX40L and TNF
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
Funding
The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery
From Platform to Precision: The $800M Bet Transforming Biotech Investing
Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins
Novo Holdings Leads $100 Million Series C Financing for Asceneuron
German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies
Brisbane Biotech Gelomics Raises $2.2 Million in Pre-Seed Funding
Aging Science
New Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated Aging
Timeline Concludes Major Immune Aging Study with Promising Results
Researchers Awarded $15 Million to Study Impact of Inflammation on Heart and Brain
Genomics
From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care
The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer
Epigenetic Stability Linked to Lifespan in Mammals, Research Show
Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development
AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development
Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing
M&A & Partnerships
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion
Biotech Stocks
Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate
Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion
Alumis IPO Priced at $16, Targets $210M Funding
Diamond Biofund Becomes First Biotech VC Firm Listed on Taiwan Stock Exchange
Psychology
Scroll to Top
